Molecular Classification
Adjuvant, Liposome-based formulation, TLR4 agonist (MPL), Saponin (QS-21)
Other Names
MPL/QS-21 liposome adjuvant, AS01, MPL, QS-21
Disease Roles
Vaccine developmentMalariaHerpes zoster/shingles

AS01E Adjuvant Overview

AS01E is a liposome-based vaccine adjuvant system containing MPL (a TLR4 agonist) and QS-21 (a saponin). It enhances immune responses by activating APCs, promoting T cell priming, and stimulating antibody production, leading to increased vaccine efficacy. It is used in vaccines against diseases such as malaria, herpes zoster, tuberculosis, and RSV.

Mechanism of Action

AS01E activates antigen-presenting cells (APCs), particularly dendritic cells, through MPL's TLR4 agonism and QS-21's immune-enhancing properties. This leads to enhanced antigen presentation, T cell priming, and B cell activation, resulting in strong Th1-biased cellular and humoral immune responses.

Biological Functions

Immune response enhancement
Innate immune system activation
Adaptive immune system stimulation
Antigen presentation
T cell priming
B cell activation
Th1 polarization

Disease Associations

Vaccine development
Malaria
Herpes zoster/shingles
Tuberculosis
Respiratory syncytial virus (RSV)

Safety Considerations

  • Mild-to-moderate local or systemic adverse reactions
  • Injection site reactions